

# Pseudomonas mallei LPS (3D11): sc-52177

## BACKGROUND

*Pseudomonas mallei* is a gram-negative, bipolar, aerobic bacterium that causes a disease known as Glanders. Glanders occurs primarily in horses, mules and donkeys, but it can be transmitted to humans from horses. Symptoms of Glanders include the development of nodular lesions in the lungs and ulceration of the mucous membranes in the upper respiratory tract. The acute form causes coughing, fever and infectious nasal discharge, closely followed by septicaemia and death. *P. mallei* is unable to survive without a host, and it primarily infects the lungs. Lipopolysaccharide (LPS) is a major component of the cell membrane of *Pseudomonas mallei*. LPS is an endotoxin that induces a strong response from normal animal immune systems and also contributes greatly to the structural integrity of the bacteria and protects its membrane from certain kinds of chemical attacks. *P. mallei* also forms a capsule made up of polysaccharide biopolymers that protect it from phagocytosis.

## REFERENCES

1. Ageeva, N.P., Merinova, L.K. and Peters, M.K. 1989. The use of the plasmid pTH10 for isolating the donor strains of *Pseudomonas mallei*. Mol. Gen. Mikrobiol. Virusol. 4: 14-18.
2. Ageeva, N.P. and Merinova, L.K. 1990. The effect of mating conditions on the effectiveness of transmitting RP4 plasmids in *Pseudomonas mallei*. Mikrobiol. Zh. 48: 3-6.
3. Pitt, T.L., Aucken, H. and Dance, D.A. 1992. Homogeneity of lipopolysaccharide antigens in *Pseudomonas pseudomallei*. J. Infect. 25: 139-146.
4. Manzeniuk, Olu., Volozhantsev, N.V., Astashkin, E.I. and Svetoch, E.A. 1993. Transduction of *Pseudomonas mallei* bacteria. Mol. Gen. Mikrobiol. Virusol. 4: 37-40.
5. Manzeniuk, I.N., Manzeniuk, Olu., Filonov, A.V., Stepanshin, Iu.G., Svetoch, E.A. 1995. Resistance of *Pseudomonas mallei* to tetracyclines: assessment of the feasibility of chemotherapy. Antibiot. Khimioter. 40: 40-44.
6. Popov, S.F., Kurilov, Vla. and Iakovlev, A.T. 1996. *Pseudomonas pseudomallei* and *Pseudomonas mallei*-capsule-forming bacteria. Zh. Mikrobiol. Epidemiol. Immunobiol. 5: 32-36.
7. Manzeniuk, I.N., Marchenko, A.I., Svetoch, E.A. 1996. The sensitivity of *Pseudomonas mallei* strains to antibacterial preparations in *in-vitro* experiments on a cell culture model. Antibiot. Khimioter. 41: 14-17.
9. Verevkin, VV., Volozhantsev, N.V., Miakinina, V.P. and Svetoch, E.A. 1997. Effect of TRA-system of plasmids RP4 and R68.45 on *Pseudomonas mallei* virulence. Vestn. Akad. Med. Nauk SSSR. 6: 37-40.

## SOURCE

*Pseudomonas mallei* LPS (3D11) is a mouse monoclonal antibody raised against cell extract of *Pseudomonas mallei*.

## PRODUCT

Each vial contains 100 µg IgG<sub>1</sub> in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

*Pseudomonas mallei* LPS (3D11) is recommended for detection of LPS of *P. mallei* of *Pseudomonas mallei* and *Pseudomonas mallei* origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.